Episode Details

Back to Episodes
Pharmaceutical Executive Daily: Merck Acquires SPR2015 in $2.13 Billion Licensing Deal

Pharmaceutical Executive Daily: Merck Acquires SPR2015 in $2.13 Billion Licensing Deal

Published 1 month, 3 weeks ago
Description
Merck licenses a preclinical KRAS G12D inhibitor from SciBrunch, FDA approves Olumiant, Juvmo, and Atebrioz across three separate indications, and Matthew Montes de Oca makes the case for compounding pharmacies to set their own safety standards.
Listen Now

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us